Caligan Partners LP

13D and 13G Filings

Issuer % of Class Filed
Schedule 13D · 2 securities · may seek to influence control
Anika Therapeutics, Inc. 13D/A
ANIK · 035255108
 10.0% 1/27/2026
Event 1/23/2026
Verrica Pharmaceuticals Inc. 13D/A
VRCA · 92511W207
 10.0% 12/30/2025
Event 12/26/2025
Schedule 13G · 9 securities · passive
SAB Biotherapeutics, Inc. 13G/A
SABS · 78397T202
 8.8% 8/14/2026
Event 6/30/2026
Avalo Therapeutics, Inc. 13G/A
AVTX · 05338F306
 5.9% 8/14/2026
Event 6/30/2026
Opus Genetics, Inc. 13G/A
IRD · 67577R102
 7.3% 8/14/2026
Event 6/30/2026
Faeth Therapeutics, Inc. 13G/A
FTH · 81728A207
 2.4% 8/14/2026
Event 6/30/2026
Cellectar Biosciences, Inc. 13G
CLRB · 15117F880
 5.9% 8/14/2026
Event 6/30/2026
LB Pharmaceuticals Inc 13G
LBRX · 50180M108
 5.0% 5/15/2026
Event 3/31/2026
Evolus, Inc. 13G/A
EOLS · 30052C107
 0% 2/17/2026
Event 12/31/2025
Y-mAbs Therapeutics, Inc. 13G/A
YMAB · 984241109
 0% 11/14/2025
Event 9/30/2025
Verrica Pharmaceuticals Inc. 13G
VRCA · 92511W108
 10.0% 2/12/2025
Event 12/31/2024

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.